Format

Send to

Choose Destination
J Alzheimers Dis. 2009;16(3):649-56. doi: 10.3233/JAD-2009-1004.

Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease.

Author information

1
Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany. thomas.leyhe@med.uni-tuebingen.de

Abstract

Preclinical and clinical studies gave evidence that lithium could be useful in the treatment of Alzheimer's disease (AD). In experimental investigations, lithium induces brain-derived neurotrophic factor (BDNF). Recent studies have found a decrease of BDNF in the serum and brains of AD patients with potentially consecutive lack of neurotrophic support. We assessed the influence of a lithium treatment on BDNF serum concentration in a subset of a greater sample recruited for a randomized, single-blinded, placebo-controlled, parallel-group multicenter 10-week study, investigating the efficacy of lithium treatment in AD patients. In AD patients treated with lithium, a significant increase of BDNF serum levels, and additionally a significant decrease of ADAS-Cog sum scores in comparison to placebo-treated patients, were found. Diminution of cognitive impairment was inversely correlated with lithium serum concentration. Upregulation of BDNF might be part of a neuroprotective effect of lithium in AD patients. The results of the present investigation encourage performing studies with longer treatment phases to observe potential positive long-term effects of lithium in AD patients.

PMID:
19276559
DOI:
10.3233/JAD-2009-1004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center